monitoring (5 non-responders, 2 complete responders, and 0 partial responders). Th e results by subject in Table 1 depict the low acid exposure across both groups with the exception of one complete responder and one non-responder.
We thank Song and colleagues for raising these important points. Although optimizing a clinical approach to suspected LPR is a major undertaking, we agree that next steps require clarifi cation of diagnostic criteria and outcome measures, and examination of non-acid refl ux mechanisms.
measures, separate out throat symptoms, redefi ne rigorous criteria for a diagnosis of LPR, and remind practitioners that all laryngeal complaints are not related to gastroesophageal refl ux.
In our study, oropharyngeal pH-monitoring results did not predict symptom response. Song and colleagues highlight that oropharyngeal pH metry does not measure weakly acidic or non-acidic refl ux burden. Advancements in the fi eld of gastroesophageal refl ux disease now provide diagnostic tools to examine non-acidrelated properties of gastroesophageal refl ux, and future research in extraesophageal syndromes should examine the role of these tests. For instance, salivary pepsin is a potentially sensitive and specifi c biomarker of gastroesophageal refl ux ( 5 ), and our prior research suggests that once appropriate thresholds are identifi ed, salivary pepsin may be a reliable biomarker of refl ux-associated laryngeal symptoms ( 6 ). Mucosal impedance, a novel tool to measure direct conductivity of the epithelium, seems to have high specifi city in distinguishing and predicting response to treatment in esophageal disorders and exploring the mucosal impedance of the laryngeal epithelium is intriguing ( 7 ).
Finally, Song and colleagues mention the potential importance of post-proton pump inhibitor therapy oropharyngeal monitoring to examine physiologic changes between responder and non-responder groups. Although our study was originally designed to study post-treatment oropharyngeal monitoring, only 7 of 34 subjects agreed to a second post-treatment oropharyngeal pH To the Editor: We thank you for the opportunity to respond to the comments of Song and colleagues ( 1,2 ). We agree that although the refl ux symptom index (RSI) questionnaire is commonly used in clinical research to examine symptom severity, the RSI has several shortcomings as an outcome metric. Th e RSI is a cumulative score based on throat symptoms and heartburn ( 3 ). Th roat symptoms include dysphonia, throat clearing, postnasal drip, globus, cough, dysphagia, and diffi culty breathing. As mentioned by Song et al. , the mechanisms and response to treatment for these individual laryngeal symptoms are diverse, and should be studied more precisely rather than lumped together in the RSI. Similarly, the editorial by Vaezi ( 4 ) explains that the RSI is problematic when examining response to acid suppression since the RSI may improve based on an isolated response to heartburn without improvement in throat symptoms. Th e limitations with the RSI allude to the overarching problem with the nebulous and overused term laryngopharyngeal refl ux (LPR). While in some cases gastroesophageal refl ux can cause laryngeal injury, nowadays, laryngeal complaints are oft en mistakenly equated with LPR, regardless of whether a true possibility of gastroesophageal refl ux exists. Moving forward, we need to identify better outcome 
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For this reason we would like to propose a paradigm shift in our understanding of the relationship between CP and PEI ( Figure 1 ). Like subclinical structural chronic pancreatitis, PEI can be an isolated symptomatic phenomenon in the absence of radiological CP changes and possibly off er an additional pathway to the deve lopment of more advanced pancreatic disease and symptoms. Th is pathway could also account for the PEI demonstrated in a proportion of diabetes patients when magnetic resonance imaging features of CP have been shown to be absent in 21% ( 6 ).
We recommend that clinicians should routinely test for PEI in patients with gastrointestinal symptoms. Th is approach has a high diagnostic yield, symptomatic benefi t with PERT and may allow early counselling for the risk factors of alcohol and smoking noted by Wilcox et al., which could in turn potentially reduce the future development of CP. Pancreatic exocrine insuffi ciency (PEI) has previously been considered to be a late development in the course of CP. However, we have recently described a PEI prevalence of 13.1% ( n =238/1821) when testing unselected symptomatic patients presenting to gastroenterology clinics across two diff erent regions in the United Kingdom. Of the 238 found to have a low fecal elastase-1 (FEL-1) measurement (<200 μ g/g), 202 out of 238 patients had pancreatic imaging. Of these cases, only 60 (29.7%) patients had radiological changes felt to be consistent with CP (calcifi cation, atrophy, duct dilatation, cystic change or pseudocysts). Within the PEI group, there was a 79.6% reported benefi t in symptoms with PERT. A unique observation not previously reported was that patients with a low FEL-1 had symptomatic benefi t from PERT irrespective of whether these patents had radiological features of CP (88.6% (31 out of 35)) or not (84.7% (72/85)) ( P =0.77) ( 5 ). 
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